Cargando…
COVID-19 and IL-6: Why vitamin D (probably) helps but tocilizumab might not
Interleukin 6 (IL-6), which is involved in the cytokine storm phenomenon, is a therapeutic target in COVID-19, but monoclonal receptor antibody therapeutic agents such as tocilizumab have demonstrated mixed results. Could Vitamin D, which modulates IL-6, be more effective than currently deployed IL-...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954769/ https://www.ncbi.nlm.nih.gov/pubmed/33722593 http://dx.doi.org/10.1016/j.ejphar.2021.174031 |